Innovative Cancer Immunotherapy Development
- Sharing how NK cell therapy combined with HAIC for advanced HCC Phase 2a results showing 68.75% ORR and 100% Disease Control Rate
- Showcasing how to best expand NK cell therapy to additional solid tumors, including small cell lung cancer (SCLC) and pancreatic ductal adenocarcinoma (PDAC), alongside emergency trial cases
- Unveiling next-generation CAR platforms, CAR-MILs for multiple myeloma and dual PD-L1/EphA2 CAR-T for solid tumors, designed to overcome antigen escape and immunosuppression